NPCE NeuroPace Inc Insider Trading

10% owner OrbiMed sold 168,136 shares ($2.7M) as stock rebounds to 52-week high of $17.49

OrbiMed Advisors LLC, a 10% shareholder in NeuroPace, executed 2 separate sales totaling 168,136 shares for $2,665,332.88 at a blended average price of $15.85 on 2025-05-14. The sale reduced the fund's stake by 4.9% to 3,238,199 shares. This transaction occurred as the stock has appreciated significantly in the recent term (30-day change: +67.7%, 90-day change: +42.1%) and now trades at the 52-week high of $17.49, above the transaction execution prices. Across OrbiMed's cross-ticker track record, the fund's 18 prior sells show an average 30-day return of -2.8%, though this particular filing does not indicate whether this sale was executed under a 10b5-1 plan. NeuroPace remains unprofitable despite strong revenue growth of 22.1% annually and recent quarterly revenue of $22,524,000.00, with a net loss of $-6,589,000.00 over the most recent quarter.

CMO Martha Morrell sold 78,334 shares (78.3K) of NPCE at $13.72; retains 81,993 shares; company unprofitable with -$5.5M net income.

Martha Morrell, Chief Medical Officer, sold 78,334 shares, reducing her holdings by 48.9% from 160,327 to 81,993 shares at $13.72. The transaction occurred when the stock was trading 19.1% below its 52-week high of $17.11 and down 5.8% over 30 days, despite a strong 35.0% 90-day gain. While NeuroPace demonstrates healthy revenue growth of 43.7% year-over-year, the company reported negative net income of $-5,452,000.00 in its latest quarter and remains unprofitable on a full-year basis. The sale represents a material reduction in the CMO's stake and occurs in the context of an unprofitable company, factors that merit investor review.

10% Owner KCK LTD. liquidates entire 5,270,845-share stake in NeuroPace at $9.40, exiting position completely.

KCK LTD., a 10% shareholder, sold 5,270,845 shares at $9.40 on 2025-02-20, reducing holdings from 5,270,845 shares to 0 shares (a -100.0% net change). The transaction was executed significantly below the current price of $14.23 and below the 52-week high of $17.50. Across the insider's prior two sales at NPCE, the stock subsequently rose 77.9% and 61.1% over 30 days, and 157.2% and 116.9% over 90 days—neither sale proved well-timed on the 90-day horizon. The company reported quarterly revenue of $21,060,000.00 and a net loss of $-5,452,000.00, with an annual revenue growth rate of +43.7% offsetting the unprofitable operating profile. A complete liquidation by a major shareholder warrants scrutiny, particularly given the insider's historical pattern of selling ahead of stock rallies at this ticker.

10% owner KCK LTD. sold 224,138 shares for $1,221,927.08 across 2 separate sales at $5.45–$6.02, retaining 5,270,845 shares.

KCK LTD., a 10% shareholder of NPCE, executed two separate sales totaling 224,138 shares at an blended average price of $5.45, reducing holdings by 4.1% to 5,270,845 shares. The sales occurred within two trading days (2024-10-23 and 2024-10-25) while the stock traded -63.5% from its 52-week high of $17.50 and at levels below the recent 52-week entry range. NPCE remains unprofitable with net income of $-7,514,000.00 in the latest quarter despite 43.7% annual revenue growth, suggesting the company is in an unprofitable growth phase. The filing reveals a material but partial liquidation of a core stakeholder position during a prolonged market downturn, at prices below the 52-week midpoint, with no scheduled-plan indicator provided.